NEWS
Print Your Certificate
The 2025 AD Scientific Index is here—explore updated university and researcher rankings!
New! Young University / Institution Rankings 2025
New! The 2025 Edition of the AD Scientific Index is now live!
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
"Exciting Update! The 2025 Edition of the AD Scientific Index is now live!
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
Eileen McCormick Holmes Wright
University of Dundee - Dundee / United Kingdom
Others
AD Scientific Index ID: 1342815
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Eileen McCormick Holmes Wright's MOST POPULAR ARTICLES
1-)
How to construct ‘normal ranges’ for fetal variablesP Royston, EM WrightUltrasound in Obstetrics and Gynecology 11 (1), 30-38, 19985061998
2-)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association …E De Azambuja, AP Holmes, M Piccart-Gebhart, E Holmes, S Di Cosimo, ...The lancet oncology 15 (10), 1137-1146, 20144642014
3-)
Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2–positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or …M Piccart-Gebhart, E Holmes, J Baselga, E De Azambuja, AC Dueck, ...Journal of Clinical Oncology 34 (10), 1034, 20163862016
4-)
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo …S Banerjee, KN Moore, N Colombo, G Scambia, BG Kim, A Oaknin, ...The Lancet Oncology 22 (12), 1721-1731, 20212882021
5-)
Goodness‐of‐fit statistics for age‐specific reference intervalsP Royston, EM WrightStatistics in medicine 19 (21), 2943-2962, 20002602000
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept